Sammarco, M.G. (M. G.)

Filtering

20192

Settings

Author search.filters.isAuthorOfPublication.2bffcfde-eac5-4998-97df-aa9c7c3e6bf1

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Review paper Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): single institution experience and systematic literature review
    (Termedia Sp. z.o.o., 2019) Martinez-Monge, R. (Rafael); Kovács, G. (Gyorgy); Sammarco, M.G. (M. G.); Azario, L. (L.); Caputo, C.G. (C. G.); Scupola, A. (A.); Gambacorta, M.A. (M. A.); Autorino, R. (R.); Valentini, V. (Vincenzo); Tagliaferri, L. (Luca); Blasi, M.A. (Maria Antonietta); Lancellotta, V. (Valentina); Fionda, B. (Bruno); Pagliara, M.M. (M. M.); Cammelli, S. (S.)
    Purpose: To report the results of a patient’s tailored therapeutic approach using a second course of interventional radiotherapy (brachytherapy) in patients with locally recurrent uveal melanoma. Material and methods: Patients who had already undergone ocular brachytherapy treated at our IOC (Interventional Oncology Center) were considered. Five patients who has received a second course of treatment with a plaque after local recurrences were included in our study. Re-irradiation was performed with Ruthenium-106 (prescribed dose to the apex 100 Gy) or with Iodine-125 plaques (prescribed dose to the apex 85 Gy). Moreover, a systematic literature search was conducted through three electronic databases, including Medline/PubMed, Scopus, and Embase. Results: All patients were initially treated with Ruthenium-106 plaque; the re-irradiation was performed with Ruthenium-106 plaque in three cases and with Iodine in two cases. Mean time between the first and the second plaque was 56.8 months (range, 25-93 months). Local tumor control rate was 100%, no patient underwent secondary enucleation owing to re-treatment failure. Distant metastasis occurred in 1 patient after 6 months from re-treatment. After a median follow-up of 44.2 months (range, 26-65 months) from re-treatment, all patients experienced worsening of the visual acuity (median visual acuity was 0.42 at time of recurrence and decline to 0.24 at the most recent follow-up); cataract occurred in two cases, no patient developed scleral necrosis. We considered 2 papers for a systematic review. Conclusions: In selected cases, especially in presence of marginal local recurrence, a personalized re-treatment strategy with a plaque may offer high probability of tumor control and organ preservation but worsening of visual acuity.
  • Thumbnail Image
    PO-1045 Retreatment using Ru-106 or I-125 plaque in uveal melanoma locally recurrent after brachytherapy
    (Elsevier BV, 2019) Martinez-Monge, R. (Rafael); Kovács, G. (Gyorgy); Sammarco, M.G. (M. G.); Azario, L. (L.); Caputo, C.G. (C. G.); Scupola, A. (A.); Blasius, B. (B.); Gambacorta, M.A. (M. A.); Autorino, R. (R.); Valentini, V. (Vincenzo); Tagliaferri, L. (Luca); Lancellotta, V. (Valentina); Fionda, B. (Bruno); Pagliara, M.M. (M. M.); Cammelli, S. (S.)
    Purpose or Objective:To present the results of a patient therapeutic approach using a second course of Interventional Radiotherapy (Brachytherapy) in a setting of patients with local recurrence of uveal melanoma. Material and Methods: Patients who had already undergone ocular brachytherapy at IOC (Interventional Oncology Center) of the “Gemelli ART” (Advanced Radiation Therapy) of Rome were considered. In this group, five patients with a local recurrence that received a second course of treatment with a plaque were included in our analysis. The reirradiation was performed with a plaque of Ruthenium-106 (dose prescribed to the apex 100 Gy) or of Iodine-125 (dose prescribed to the apex 85Gy).